Bleomycin Containing Chemotherapeutic Regimen Induced Acquired Partial Lipodystrophy

Area of Science:

• Oncology
• Dermatology
• Pharmacology

Background:

• Bleomycin is a chemotherapy agent known for its toxicity, primarily affecting the skin and lungs.
• Classic cutaneous side effects include flagellate erythema and drug rash.
• Acquired partial lipodystrophy is a rare condition characterized by localized fat loss.

Purpose of the Study:

• To report an unusual case of bleomycin-induced acquired partial lipodystrophy.
• To highlight a rare dermatological adverse effect of bleomycin with potential cosmetic implications.
• To discuss the management and implications in a young female patient treated for ovarian germ cell tumor.

Main Methods:

• Case report of a young woman treated with bleomycin postoperatively for ovarian endodermal sinus tumor.
• Clinical observation and documentation of the dermatological adverse event.
• Review of literature on bleomycin-induced cutaneous toxicities and lipodystrophy.

Main Results:

• The patient developed an isolated form of acquired partial lipodystrophy.
• This condition presented as localized fat atrophy, distinct from typical bleomycin-induced rashes.
• The lipodystrophy had significant cosmetic implications for the patient.

Conclusions:

• Bleomycin can induce rare cutaneous adverse effects beyond flagellate erythema and drug rash, including acquired partial lipodystrophy.
• Clinicians should be aware of this potential side effect, especially in patients receiving bleomycin for malignancies.
• Early recognition and management are crucial, considering the cosmetic and psychological impact on patients.